Global Arteriosclerosis Therapeutics Market Size By Type (Medicine, Surgery), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Arteriosclerosis Therapeutics Market was valued at USD 14.1 billion in 2023 and is projected to surpass USD 24.8 billion by 2031, growing at a CAGR of 7.4% during the forecast period of 2023–2031. The market growth is driven by the increasing prevalence of cardiovascular diseases, rising geriatric population, and the growing demand for advanced and targeted treatment options for arteriosclerosis. Continuous advancements in pharmaceutical research and a strong product pipeline further boost the market outlook.

Drivers:

1. Rising Incidence of Cardiovascular Diseases

Arteriosclerosis is a leading contributor to cardiovascular morbidity and mortality. With lifestyle-related risk factors such as obesity, diabetes, smoking, and hypertension on the rise globally, the demand for effective arteriosclerosis therapeutics is surging.

2. Advancements in Drug Development

Breakthroughs in biologics, statins, and anti-inflammatory agents are contributing significantly to market growth. Companies are investing heavily in R&D, resulting in the development of more precise and effective therapeutic options.

3. Increasing Geriatric Population

Aging is a key risk factor for arteriosclerosis. The growing elderly population globally is increasing the patient pool, thereby driving demand for therapeutics aimed at managing arterial stiffness and plaque accumulation.

Restraints:

1. High Cost of Treatment

The cost of long-term treatment for arteriosclerosis, especially with novel biologics and targeted drugs, remains high. This can restrict patient access, particularly in low- and middle-income countries.

2. Stringent Regulatory Approvals

The complexity of clinical trials and regulatory scrutiny required for cardiovascular drugs can delay product launches and restrict the entry of new therapeutics into the market.

Opportunity:

1. Personalized Medicine & Biomarker-Based Therapy

The emergence of personalized treatment approaches and biomarker-guided therapies holds promising potential for more effective treatment outcomes. These innovations can drive significant future growth in the arteriosclerosis therapeutics market.

2. Expansion in Emerging Markets

Increasing healthcare infrastructure, insurance coverage, and awareness campaigns in Asia-Pacific, Latin America, and the Middle East are creating substantial growth opportunities for market players in these regions.

Market by System Type Insights:

Based on drug class, the Statins segment accounted for the largest share in 2023, due to their proven efficacy in lowering LDL cholesterol levels and preventing plaque buildup. However, the PCSK9 inhibitors segment is projected to witness the fastest growth rate owing to superior outcomes in high-risk patients and increasing clinical acceptance.

Market by End-use Insights:

By end-use, Hospital Pharmacies held the dominant share in 2023, attributed to the high volume of prescriptions and the availability of advanced cardiovascular care. Meanwhile, the Online Pharmacies segment is projected to grow rapidly due to increasing digital health adoption, convenience, and rising home-care trends.

Market by Regional Insights:

North America led the global arteriosclerosis therapeutics market in 2023, driven by robust healthcare infrastructure, high awareness levels, and significant R&D investments. Asia-Pacific is expected to witness the fastest CAGR through 2031, fueled by increasing prevalence of lifestyle diseases, healthcare spending, and pharmaceutical expansion in countries like China and India.

Competitive Scenario:

Key players in the market include Pfizer Inc., AstraZeneca PLC, Merck & Co., Inc., Amgen Inc., Sanofi S.A., Novartis AG, Bayer AG, Bristol-Myers Squibb, Abbott Laboratories, and Boehringer Ingelheim. These companies are focusing on clinical trials, strategic collaborations, and innovation in lipid-lowering and anti-inflammatory therapies.

Key Market Developments:

2023: Amgen expanded its Repatha (PCSK9 inhibitor) access in emerging markets through new regional distribution partnerships.

2024: Pfizer initiated Phase III trials for a novel anti-inflammatory biologic targeting arterial plaque regression.

2025: Sanofi and Regeneron received FDA fast-track designation for their combination therapy targeting advanced arteriosclerosis in diabetic patients.

Scope of Work – Global Arteriosclerosis Therapeutics Market

Report Metric Details

Market Size (2023) USD 14.1 billion

Projected Market Size (2031) USD 24.8 billion

CAGR (2023–2031) 7.4%

Market Segments By Drug Class (Statins, PCSK9 Inhibitors, etc.), End-use

Growth Drivers Rising CVD prevalence, aging population, drug innovation

Opportunities Biomarker therapies, emerging markets expansion

FAQs:

1) What is the current market size of the Global Arteriosclerosis Therapeutics Market?

The market was valued at USD 14.1 billion in 2023.

2) What is the major growth driver of the Global Arteriosclerosis Therapeutics Market?

The major driver is the rising incidence of cardiovascular diseases globally.

3) Which is the largest region during the forecast period in the Global Arteriosclerosis Therapeutics Market?

North America is expected to remain the largest region throughout the forecast period.

4) Which segment accounted for the largest market share in the Global Arteriosclerosis Therapeutics Market?

The Statins segment held the largest market share in 2023.

5) Who are the key market players in the Global Arteriosclerosis Therapeutics Market?

Pfizer Inc., AstraZeneca PLC, Merck & Co., Inc., Amgen Inc., and Sanofi S.A. are among the key players.